Prosecution Insights
Last updated: August 16, 2026
Application No. 18/412,997

CYCLOSILAZANE PRECURSORS AND RELATED METHODS

Final Rejection §112
Filed
Jan 15, 2024
Priority
Jan 17, 2023 — provisional 63/439,331
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Entegris Inc.
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1430 granted / 1769 resolved
+20.8% vs TC avg
Minimal -15% lift
Without
With
+-15.2%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
51 currently pending
Career history
1810
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
14.9%
-25.1% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
43.5%
+3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1769 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on June 2, 2026, the applicants have canceled claim 3; amended claims 1-2, 4-9, 15 and 16 and furthermore, have added new claims 21 and 22. Claims 1-2 and 4-22 are pending in the application. Response to Arguments Applicant's arguments filed June 2, 2026 have been fully considered but they are not persuasive regarding indefiniteness rejection of claims 2 and 4-9 as well as regarding prior art rejection of claims 10 and 12-15 over Wannagat’s reference. The applicants have amended claims to overcome all other rejections. Regarding indefiniteness rejection of claims 2 and 4-9, the applicants argue on page 21 that claims are amended to overcome this rejection. This is not true. Claims 2 and 4-9 still lack antecedent basis for composition in claim 1. In regard to prior art rejection over Wannagat’s reference, the applicants argue on pages 24-25 that this reference does not anticipate the instant claims 10 and 12-15. The examiner does not agree with these arguments. The applicant’s attention is drawn to page 48 of this reference. On page 48, Wannagat teaches preparing compound B by using two different processes, each using two intermediates. The process for preparing compound B on the left side does anticipate the instant claims when variables R1-R5 represent methyl groups. Conclusion The indefiniteness rejection of claims 2 and 4-9 under 35 USC 112, 2nd paragraph is maintained. The prior art rejection of claims 10 and 12-15 under 35 USC 102(a) (1) over Wannagat is maintained. NEW GROUNDS OF REJECTION Claim Rejections - 35 USC § 112 7. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 21 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 21 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Claims 1 and 16-20 are allowed. Claims 11 and 22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 15, 2024
Application Filed
Mar 02, 2026
Non-Final Rejection mailed — §112
Jun 02, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703690
PROCESS FOR PREPARING ALKYL-4-OXOTETRAHYDROFURAN-2-CARBOXYLATE
2y 11m to grant Granted Aug 11, 2026
Patent 12698290
SYNTHETIC METHODS AND INTERMEDIATES FOR PRODUCING COMPOUNDS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
2y 11m to grant Granted Aug 04, 2026
Patent 12692244
GRISEOFULVIN 4 POSITION ETHERIFIED DERIVATIVES AND THEIR APPLICATION
2y 6m to grant Granted Jul 28, 2026
Patent 12692259
Morpholine-Containing & Piperazine-Containing CXCR4 Modulators and Uses Related Thereto
2y 6m to grant Granted Jul 28, 2026
Patent 12679846
NOVEL XANTHONE COMPOUND HAVING EXCELLENT ANTICANCER EFFECT
2y 7m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-15.2%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1769 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month